COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
05/12/2025
Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
05/12/2025
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
05/12/2025
Ghent, Belgium, Dec. 05, 2025 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION 5 December 2025, 6:00 pm CET Ghent, Belgium, 5 December 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025
05/12/2025
VALNEVA Déclaration d’actions et de droits de vote 30 novembre 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
VALNEVA Declaration of shares and voting rights: November 30, 2025
05/12/2025
VALNEVA Declaration of shares and voting rights November 30, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
05/12/2025
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and [...]
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
05/12/2025
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be [...]
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
05/12/2025
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire : — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand [...]
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
05/12/2025
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity [...]
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
05/12/2025
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced [...]
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
05/12/2025
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability to attain and regain [...]
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
05/12/2025
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in [...]
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
05/12/2025
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study to evaluate a STAT3 inhibitor in IPF patients refreshed an old debate regarding the feasibility to develop [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
05/12/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 5 December 2025 at 17.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
05/12/2025
Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, [...]
Curaechoice and Northwestern Memorial Healthcare Extend Partnership to Expand Access to No-Cost Healthcare for Curaechoice Members Nationwide
05/12/2025
Birmingham, Alabama , Dec. 05, 2025 (GLOBE NEWSWIRE) -- Curaechoice , the nation’s #1 leader in No-Cost Benefits Optimization Solutions, and Northwestern Memorial Healthcare, one of the country’s most respected and [...]
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
05/12/2025
SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
05/12/2025
MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical [...]
Immatics Announces $125 Million Underwritten Offering
05/12/2025
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, [...]

Pages